Novartis Korea, Dongwha to co-market Theraflu

Published: 2009-10-26 06:57:00

Updated: 2009-10-26 06:57:00

Novartis Korea and Dongwha Pharm announced on October 21 that they have recently signed an agreement to co-market TheraFlu, a brand of over-the-counter cold and flu medicines that contain different groupings of various cold and flu symptom medications.

TheraFlu is produced in several forms an...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK